Results 161 to 170 of about 36,256 (261)

Combining immunotherapy with radiation therapy in thoracic oncology [PDF]

, 2018
Badiyan, Shahed N, Chilukuri, Srinivas, Chuong, Michael D, Glass, Erica, Mohindra, Pranshu, Onyeuku, Nasarachi E, Remick, Jill, Rice, Stephanie R, Roach, Michael C, Simone, Charles B, II   +9 more
core   +1 more source

PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer

, 2020
Fahad Shabbir Ahmed, Patricia Gaule, John J. McGuire, Katir Patel, Kim Blenman, Lajos Pusztai, David L. Rimm   +6 more
openalex   +2 more sources

Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted Management of Oral and Head and Neck Squamous Cell Carcinoma [PDF]

Piotr Kawczak, Igor Feszak, Tomasz Bączek   +2 more
openalex   +1 more source

Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer

, 2022
Ting Xu, Lirong Wu, Saumil Gandhi, Jing Wang, Quyhn-Nhu Nguyen, Aileen B. Chen, Joe Y. Chang, Roza Nurieva, Ajay Sheshadri, Mehmet Altan, Percy P. Lee, Steven H. Lin, Zhongxing Liao   +12 more
openalex   +2 more sources

New-Onset Guttate Psoriasis Induced by Durvalumab: Potential Role of Bisoprolol. [PDF]

Cureus
Tshika Wa Kabeya O, Kaziga Wiyaou DD, Moustaghfir I.   +2 more
europepmc   +1 more source

Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? [PDF]

, 2017

core   +1 more source

Successful Conversion Surgery after Tremelimumab plus Durvalumab Therapy for Unresectable Recurrent Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Case Report

Yuhi Yoshizaki, Fuyuki Inagaki, Takashi Kokudo, Fuminori Mihara, Yasushi Kojima, Hideki T. Miyazaki, Toru Igari, Norihiro Kokudo   +7 more
openalex   +2 more sources

Effect of Butyrate-Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab. [PDF]

JGH Open
Nouso K, Wakuta A, Shiota S, Fujita R, Kariyama K, Hiraoka A, Atsukawa M, Tani J, Tada T, Nakamura S, Tajiri K, Kaibori M, Hirooka M, Itobayashi E, Kakizaki S, Naganuma A, Ishikawa T, Imai M, Aoki T, Tanaka H, Hatanaka T, Tsuji K, Kawata K, Takaguchi K, Tsutsui A, Ogawa C, Ochi H, Yata Y, Kuroda H, Matono T, Yasuda S, Toyoda H, Iijima H, Kudo M, Kumada T.   +34 more
europepmc   +1 more source

Durvalumab in frail and elder patients with stage four NSCLC: Study protocol of the randomized phase II DURATION trial [PDF]

, 2019
Jonas Kuon, Adriane Hommertgen, Johannes Krisam, Felix Lasitschka, Albrecht Stenzinger, Farastuk Bozorgmehr, Martin Maenz, Meinhard Kieser, Marc A. Schneider, Michael Thomas   +9 more
openalex   +1 more source

Immunotherapy-Related Gastritis in Small Cell Lung Cancer Treatment With Durvalumab-A Case Report. [PDF]

Cancer Rep (Hoboken)
Cavaliere MC, Spadafora S, Febbraro M.
europepmc   +1 more source